These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17125403)

  • 21. A decade of drug metabolite safety testing: industry and regulatory shared learning.
    Luffer-Atlas D; Atrakchi A
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):897-900. PubMed ID: 28797172
    [No Abstract]   [Full Text] [Related]  

  • 22. In biomarkers we trust?
    Baker M
    Nat Biotechnol; 2005 Mar; 23(3):297-304. PubMed ID: 15765081
    [No Abstract]   [Full Text] [Related]  

  • 23. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives.
    Shegokar R; Müller RH
    Int J Pharm; 2010 Oct; 399(1-2):129-39. PubMed ID: 20674732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of mass spectrometry for in-vitro ADME assays.
    Chu I; Nomeir AA
    Curr Drug Metab; 2006 Jun; 7(5):467-77. PubMed ID: 16787156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preface of EuPAT 7 Special Issue - Inventing Tomorrow's Development and Manufacturing.
    Rantanen J; Khinast J
    Eur J Pharm Sci; 2016 Jul; 90():1. PubMed ID: 27324754
    [No Abstract]   [Full Text] [Related]  

  • 26. High throughput assay technologies for ion channel drug discovery.
    Zheng W; Spencer RH; Kiss L
    Assay Drug Dev Technol; 2004 Oct; 2(5):543-52. PubMed ID: 15671652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Straightforward recursive partitioning model for discarding insoluble compounds in the drug discovery process.
    Lamanna C; Bellini M; Padova A; Westerberg G; Maccari L
    J Med Chem; 2008 May; 51(10):2891-7. PubMed ID: 18419111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Theme issue "Solid state and solid dosage forms".
    Kleinebudde P
    Eur J Pharm Biopharm; 2009 Jan; 71(1):1. PubMed ID: 18817869
    [No Abstract]   [Full Text] [Related]  

  • 30. Hit discovery and hit-to-lead approaches.
    Keseru GM; Makara GM
    Drug Discov Today; 2006 Aug; 11(15-16):741-8. PubMed ID: 16846802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of Pfizer compounds in EPA's ToxCast chemicals-assay space.
    Shah F; Greene N
    Chem Res Toxicol; 2014 Jan; 27(1):86-98. PubMed ID: 24328225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of exploratory drug metabolism and pharmacokinetics in new drug research: case study-selection of a thrombin receptor antagonist for development.
    Hsieh Y; Cheng KC; Wang Y; Chackalamannil S; Xia Y; Korfmacher WA; White RE
    Curr Pharm Des; 2009; 15(19):2262-9. PubMed ID: 19601827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Industrially feasible alternative approaches in the manufacture of solid dispersions: a technical report.
    Karanth H; Shenoy VS; Murthy RR
    AAPS PharmSciTech; 2006 Oct; 7(4):87. PubMed ID: 17233539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compound selection for development - is salt formation the ultimate answer? Experiences with an extended concept of the "100mg approach".
    Korn C; Balbach S
    Eur J Pharm Sci; 2014 Jun; 57():257-63. PubMed ID: 24036162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-Generation Pharmaceutical Proteins-EUFEPS Workshop on Optimizing Biotech Medicines.
    Pasut G; Veronese FM
    IDrugs; 2007 Mar; 10(3):162-4. PubMed ID: 17351866
    [No Abstract]   [Full Text] [Related]  

  • 37. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
    Hewitt NJ; de Kanter R; LeCluyse E
    Chem Biol Interact; 2007 May; 168(1):51-65. PubMed ID: 17239835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives on bioanalytical mass spectrometry and automation in drug discovery.
    Janiszewski JS; Liston TE; Cole MJ
    Curr Drug Metab; 2008 Nov; 9(9):986-94. PubMed ID: 18991596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in intravenous delivery of poorly water-soluble compounds.
    Shi Y; Porter W; Merdan T; Li LC
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1261-82. PubMed ID: 19941409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High throughput solubility measurement in drug discovery and development.
    Alsenz J; Kansy M
    Adv Drug Deliv Rev; 2007 Jul; 59(7):546-67. PubMed ID: 17604872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.